Tagged with

CRO Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation in the local life science industry.   What have been some of the main changes for PAREXEL in Korea since…

universal healthcare Healthcare is one of the next items on President Peña Nieto’s busy agenda. The objective: moving Mexico towards universal healthcare coverage. The initiative was started at the beginning of 2000 by the previous government with the objective of ensuring in the long term that “any Mexican – employed or unemployed…

Boehringer Ingelheim Javier Castro came from Boehringer Ingelheim’s headquarters to run the Peruvian affiliate in January 2015, bringing with him a wealth of experience necessary to take the company to the next level. He discusses market access, reimbursement and new launches that BI plans to bring to Peru.   What are your…

contract manufacturing The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation.   Where did your idea for starting Korea Pharma come from? I am a pharmacist by training, and graduated from Yeong-nam University’s college of pharmacy. After graduation, I worked for Seoul Pharmaceutical Company for five…

UCB Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance of valuing innovation above cost in Korea.   What have been the most notable differences between the market situations in…

Yungjin The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010.   To begin, could you please introduce yourself, and Yungjin? Yungjin has a long history; it is one of the oldest pharmaceutical companies in Korea, having…

insurance The national coordinator of Plan Nacer and Plan Sumar – two social security programs to improve access to healthcare in Argentina – discusses universal coverage as a constitutional right, and the history of the two programs so far.    Can you please give our readers a brief summary of the activities…

CRO A senior director for Icon plc discusses Argentina’s strengths and weaknesses as a venue for clinical trials, the role the market plays in a global clinical trial strategy, and Icon’s ambitions for growth in the region.   What are Argentina’s strategic advantages in terms of clinical trial strategy? Argentina in…

clinical trials Dr. Wanda Dobrzanski discusses Argentina’s potential and attractiveness as a clinical research environment and the biggest challenges facing local and global CROs in Argentina.   How has political and popular opposition to clinical trials in Argentina changed over the last five years? Five years ago, the perception of clinical trials…

Alexion Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put in place, and how Alexion is communicating with patients’ associations and medical community to raise awareness about ultra-rare diseases.  …

MoH Dr. José Angel Cordova Villalobos shares his experience as former Minister of Health and illustrates how the unification of today’s fragmented healthcare system is the only way to provide effective healthcare to the Mexican population and how prevention is key to tackle the increasing challenges the country is facing due…

CRO The opening of the Mexican Social Security Institute (IMSS) to clinical research is a unique opportunity for Mexico to step up on the international scenario for clinical trials. The CEO of Innovare explains how the company is betting on Mexico to conduct clinical R&D and help companies bring innovative drugs to…